HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Acotec Scientific Holdings (6669.HK) - Logic Behind Boston Scientific’s Partial Offer and the Impact

Merck Puts Eye-Popping $9.3B in ADC Deal with Kelun - The "New Story" Is About to Begin

China Says Goodbye to COVID-19 and Reopens Borders - Here Are Some Points Worth the Attention

BeiGene (6160.HK/BGNE.US) 22Q3 - The Price of Being an “Outlier”

Akeso Biopharma Placement (9926.HK) - The Concerns Behind and the Outlook

Akeso Biopharma (9926.HK) - The Recent Business Progress, the Valuation and the Challenges

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/akeso-biopharma-inc" target="_blank" data-smartkarma-citation="entities:28830:1" rel="noopener">Akeso Biopharma Inc (9926 HK)</a> and Summit Therapeutics entered into a collaborative and licensing agreement for AK112, which has set a new record for China's innovative drug license-out cooperation. </li>
<li>While the market remained positive about the transaction, there are also doubts. We deep dive the potential logic of the deal. </li>
<li>We recommended investors not to neglect “the nature of the deal” and “the real motivation” behind. It’s also important to see whether the subsequent operations can make some achievements overseas.</li>
</ul>



Akeso Biopharma Inc (9926 HK) and Summit Therapeutics entered into a collaborative and licensing agreement for AK112, which has set a new record for China's innovative drug license-out cooperation. 
While the market remained positive about the transaction, there are also doubts. We deep dive the potential logic of the deal. 
We recommended investors not to neglect “the nature of the deal” and “the real motivation” behind. It’s also important to see whether the subsequent operations can make some achievements overseas.


Akeso Biopharma (9926.HK) - Behind the Deal with Summit: A Snake Swallows an Elephant?